Clinical Trials
32
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (27 trials with phase data)• Click on a phase to view related trials
The Impact of OliPhenolia® Supplementation on Exercise Induced Inflammation and Functional Movement in Humans.
- Conditions
- Healthy
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Anglia Ruskin University
- Target Recruit Count
- 24
- Registration Number
- NCT07008586
- Locations
- 🇬🇧
Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University,, Cambridge, United Kingdom
The Impact of NICU Music Therapy for Preterm Infants and Caregivers
- Conditions
- Premature Birth
- First Posted Date
- 2025-02-25
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Anglia Ruskin University
- Target Recruit Count
- 28
- Registration Number
- NCT06844396
Video-recOrded hospItal dischaRge (VOIR)
- Conditions
- ALL, Adult
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Anglia Ruskin University
- Target Recruit Count
- 60
- Registration Number
- NCT06512272
Bioavailability of Hydroxytyrosol in Healthy Adult Humans
- Conditions
- Healthy
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Anglia Ruskin University
- Target Recruit Count
- 8
- Registration Number
- NCT06285682
- Locations
- 🇬🇧
Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, United Kingdom
Neural Mechanisms of Music Intervention Chronic Arm Hemiparesis Following Stroke: A Single Case Series EEG Study
- Conditions
- HemiparesisStrokeHome-based
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Anglia Ruskin University
- Target Recruit Count
- 5
- Registration Number
- NCT06223529
- Locations
- 🇬🇧
Cambridgeshire COmmunity Services NHS Trust, Bedford, Bedfordshire, United Kingdom
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
Breakthrough Immunotherapy Combination Shows Promise Against Common Colorectal Cancer in Phase 1 Trial
A phase 1 trial of 148 patients demonstrated that the combination of botensilimab and balstilimab immunotherapy drugs successfully treated microsatellite stable metastatic colorectal cancer, the most common form that has historically not responded to immunotherapy.